Metabolomics Applications in Precision Medicine: An Oncological Perspective

Overview

Journal Curr Top Med Chem

Publisher Bentham Science Publishers

Specialty Chemistry

Date 2017 Jul 8

PMID 28685691

Citations 47

Authors

Leonor Puchades-Carrasco

Antonio Pineda-Lucena

Affiliations

Soon will be listed here.

Abstract

Nowadays, cancer therapy remains limited by the conventional one-size-fits-all approach. In this context, treatment decisions are based on the clinical stage of disease but fail to ascertain the individual ´s underlying biology and its role in driving malignancy. The identification of better therapies for cancer treatment is thus limited by the lack of sufficient data regarding the characterization of specific biochemical signatures associated with each particular cancer patient or group of patients. Metabolomics approaches promise a better understanding of cancer, a disease characterized by significant alterations in bioenergetic metabolism, by identifying changes in the pattern of metabolite expression in addition to changes in the concentration of individual metabolites as well as alterations in biochemical pathways. These approaches hold the potential of identifying novel biomarkers with different clinical applications, including the development of more specific diagnostic methods based on the characterization of metabolic subtypes, the monitoring of currently used cancer therapeutics to evaluate the response and the prognostic outcome with a given therapy, and the evaluation of the mechanisms involved in disease relapse and drug resistance. This review discusses metabolomics applications in different oncological processes underlining the potential of this omics approach to further advance the implementation of precision medicine in the oncology area.

Citing Articles

Decoding the mechanisms behind second primary cancers.

Zeng M, Lin A, Jiang A, Qiu Z, Zhang H, Chen S J Transl Med. 2025; 23(1):115.

PMID: 39856672 PMC: 11762917. DOI: 10.1186/s12967-025-06151-9.

Personalized Medicine Approach to Proteomics and Metabolomics of Cytochrome P450 Enzymes: A Narrative Review.

Fetse J, Olawode E, Deb S Eur J Drug Metab Pharmacokinet. 2024; 49(6):661-676.

PMID: 39269556 DOI: 10.1007/s13318-024-00912-5.

Emerging biomarkers for non-invasive diagnosis and treatment of cancer: a systematic review.

Zakari S, Niels N, Olagunju G, Nnaji P, Ogunniyi O, Tebamifor M Front Oncol. 2024; 14:1405267.

PMID: 39132504 PMC: 11313249. DOI: 10.3389/fonc.2024.1405267.

A non-invasive method for concurrent detection of multiple early-stage cancers in women.

Gupta A, Siddiqui Z, Sagar G, Rao K, Saquib N Sci Rep. 2023; 13(1):19083.

PMID: 37925521 PMC: 10625604. DOI: 10.1038/s41598-023-46553-7.

Microbiome and metabolic features of tissues and feces reveal diagnostic biomarkers for colorectal cancer.

Feng J, Gong Z, Sun Z, Li J, Xu N, Thorne R Front Microbiol. 2023; 14:1034325.

PMID: 36712187 PMC: 9880203. DOI: 10.3389/fmicb.2023.1034325.

References

Dighiero G, Maloum K, Desablens B, Cazin B, Navarro M, Leblay R . Chlorambucil in indolent chronic lymphocytic leukemia. French Cooperative Group on Chronic Lymphocytic Leukemia. N Engl J Med. 1998; 338(21):1506-14. DOI: 10.1056/NEJM199805213382104. View

Zahreddine H, Borden K . Mechanisms and insights into drug resistance in cancer. Front Pharmacol. 2013; 4:28. PMC: 3596793. DOI: 10.3389/fphar.2013.00028. View

Forbes S, Beare D, Gunasekaran P, Leung K, Bindal N, Boutselakis H . COSMIC: exploring the world's knowledge of somatic mutations in human cancer. Nucleic Acids Res. 2014; 43(Database issue):D805-11. PMC: 4383913. DOI: 10.1093/nar/gku1075. View

Donato N, Wu J, Stapley J, Gallick G, Lin H, Arlinghaus R . BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571. Blood. 2003; 101(2):690-8. DOI: 10.1182/blood.V101.2.690. View

Konstantinidis I, Warshaw A, Allen J, Blaszkowsky L, Fernandez-Del Castillo C, Deshpande V . Pancreatic ductal adenocarcinoma: is there a survival difference for R1 resections versus locally advanced unresectable tumors? What is a "true" R0 resection?. Ann Surg. 2012; 257(4):731-6. DOI: 10.1097/SLA.0b013e318263da2f. View

Everett J, Loo R, Pullen F . Pharmacometabonomics and personalized medicine. Ann Clin Biochem. 2013; 50(Pt 6):523-45. DOI: 10.1177/0004563213497929. View

Evans W, Johnson J . Pharmacogenomics: the inherited basis for interindividual differences in drug response. Annu Rev Genomics Hum Genet. 2001; 2:9-39. DOI: 10.1146/annurev.genom.2.1.9. View

Kanehisa M, Goto S . KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 1999; 28(1):27-30. PMC: 102409. DOI: 10.1093/nar/28.1.27. View

Asiago V, Alvarado L, Shanaiah N, Gowda G, Owusu-Sarfo K, Ballas R . Early detection of recurrent breast cancer using metabolite profiling. Cancer Res. 2010; 70(21):8309-18. PMC: 2995269. DOI: 10.1158/0008-5472.CAN-10-1319. View

10.

Tenori L, Oakman C, Morris P, Gralka E, Turner N, Cappadona S . Serum metabolomic profiles evaluated after surgery may identify patients with oestrogen receptor negative early breast cancer at increased risk of disease recurrence. Results from a retrospective study. Mol Oncol. 2014; 9(1):128-39. PMC: 5528693. DOI: 10.1016/j.molonc.2014.07.012. View

11.

Miolo G, Muraro E, Caruso D, Crivellari D, Ash A, Scalone S . Pharmacometabolomics study identifies circulating spermidine and tryptophan as potential biomarkers associated with the complete pathological response to trastuzumab-paclitaxel neoadjuvant therapy in HER-2 positive breast cancer. Oncotarget. 2016; 7(26):39809-39822. PMC: 5129972. DOI: 10.18632/oncotarget.9489. View

12.

Chambless L, Parker S, Hassam-Malani L, McGirt M, Thompson R . Type 2 diabetes mellitus and obesity are independent risk factors for poor outcome in patients with high-grade glioma. J Neurooncol. 2011; 106(2):383-9. DOI: 10.1007/s11060-011-0676-4. View

13.

Zhan H, Ciano K, Dong K, Zucker S . Targeting glutamine metabolism in myeloproliferative neoplasms. Blood Cells Mol Dis. 2015; 55(3):241-7. PMC: 5105231. DOI: 10.1016/j.bcmd.2015.07.007. View

14.

Walther Z, Sklar J . Molecular tumor profiling for prediction of response to anticancer therapies. Cancer J. 2011; 17(2):71-9. DOI: 10.1097/PPO.0b013e318212dd6d. View

15.

Boros L, Brackett D, Harrigan G . Metabolic biomarker and kinase drug target discovery in cancer using stable isotope-based dynamic metabolic profiling (SIDMAP). Curr Cancer Drug Targets. 2003; 3(6):445-53. DOI: 10.2174/1568009033481769. View

16.

Rosenwald A, Alizadeh A, Widhopf G, Simon R, Davis R, Yu X . Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia. J Exp Med. 2001; 194(11):1639-47. PMC: 2193523. DOI: 10.1084/jem.194.11.1639. View

17.

Backshall A, Sharma R, Clarke S, Keun H . Pharmacometabonomic profiling as a predictor of toxicity in patients with inoperable colorectal cancer treated with capecitabine. Clin Cancer Res. 2011; 17(9):3019-28. DOI: 10.1158/1078-0432.CCR-10-2474. View

18.

Clayton T, Baker D, Lindon J, Everett J, Nicholson J . Pharmacometabonomic identification of a significant host-microbiome metabolic interaction affecting human drug metabolism. Proc Natl Acad Sci U S A. 2009; 106(34):14728-33. PMC: 2731842. DOI: 10.1073/pnas.0904489106. View

19.

Ward P, Patel J, Wise D, Abdel-Wahab O, Bennett B, Coller H . The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. Cancer Cell. 2010; 17(3):225-34. PMC: 2849316. DOI: 10.1016/j.ccr.2010.01.020. View

20.

Holmes E, Wilson I, Nicholson J . Metabolic phenotyping in health and disease. Cell. 2008; 134(5):714-7. DOI: 10.1016/j.cell.2008.08.026. View